Ex vivo activation of immune cells
US5766920A · kind A · utility
40Cited by
17References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 6, 1995 |
| Grant date | Jun 16, 1998 |
| Priority date | — |
| Expiry date | Jan 6, 2015 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2502/11
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a process of activating patient-derived mononuclear cells by exposing the cells in vitro to substances wo generate immunoreactive cells. The ex vivo activated cells are then reinfused into the patient to enhance the immune system to treat various forms of cancer, infectious diseases, autoimmune diseases or immune deficiency diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.